JPH08503928A - 安定な高濃度のフルオレセイン製剤 - Google Patents
安定な高濃度のフルオレセイン製剤Info
- Publication number
- JPH08503928A JPH08503928A JP6506874A JP50687494A JPH08503928A JP H08503928 A JPH08503928 A JP H08503928A JP 6506874 A JP6506874 A JP 6506874A JP 50687494 A JP50687494 A JP 50687494A JP H08503928 A JPH08503928 A JP H08503928A
- Authority
- JP
- Japan
- Prior art keywords
- fluorescein
- cyclodextrin
- solution
- hydroxypropyl
- μmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92810695.4 | 1992-09-10 | ||
| EP92810695 | 1992-09-10 | ||
| PCT/EP1993/002367 WO1994005331A1 (de) | 1992-09-10 | 1993-09-02 | Stabile hochkonzentrierte formulierungen von fluoresceinderivaten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08503928A true JPH08503928A (ja) | 1996-04-30 |
Family
ID=8211984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6506874A Pending JPH08503928A (ja) | 1992-09-10 | 1993-09-02 | 安定な高濃度のフルオレセイン製剤 |
Country Status (9)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7390668B2 (en) * | 1996-10-30 | 2008-06-24 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for photodynamic treatment of disease |
| US8557298B2 (en) | 1998-08-06 | 2013-10-15 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
| US7704756B2 (en) * | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
| EP1638508B1 (en) * | 2003-06-16 | 2014-08-13 | Solx, Inc. | Shunt for the treatment of glaucoma |
| EP1715799A4 (en) * | 2004-01-22 | 2010-06-02 | Solx Inc | METHOD FOR TREATING GLAUCOMA |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| FR2611141B1 (fr) * | 1987-02-20 | 1991-02-01 | Int Rech Cancer Centre | Ensemble ou kit pour utilisation comme agent pour la destruction selective de cellules transformees ou tumorales |
| US5227372A (en) * | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
-
1992
- 1992-09-19 TW TW081107414A patent/TW251236B/zh active
-
1993
- 1993-09-02 CA CA002143115A patent/CA2143115A1/en not_active Abandoned
- 1993-09-02 KR KR1019950700947A patent/KR950703365A/ko not_active Application Discontinuation
- 1993-09-02 EP EP93919243A patent/EP0663838A1/de not_active Ceased
- 1993-09-02 AU AU49561/93A patent/AU4956193A/en not_active Abandoned
- 1993-09-02 JP JP6506874A patent/JPH08503928A/ja active Pending
- 1993-09-02 WO PCT/EP1993/002367 patent/WO1994005331A1/de not_active Application Discontinuation
- 1993-09-02 US US08/392,993 patent/US5573773A/en not_active Expired - Fee Related
-
1995
- 1995-03-08 FI FI951092A patent/FI951092A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US5573773A (en) | 1996-11-12 |
| WO1994005331A1 (de) | 1994-03-17 |
| KR950703365A (ko) | 1995-09-20 |
| AU4956193A (en) | 1994-03-29 |
| TW251236B (US20100012521A1-20100121-C00001.png) | 1995-07-11 |
| EP0663838A1 (de) | 1995-07-26 |
| FI951092A0 (fi) | 1995-03-08 |
| FI951092A (fi) | 1995-03-08 |
| CA2143115A1 (en) | 1994-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6248734B1 (en) | Use of photodynamic therapy for prevention of secondary cataracts | |
| USRE37180E1 (en) | Photochemotherapeutical obstruction of newly-formed blood vessels | |
| KR101962991B1 (ko) | 안질환 및 질병 치료용 박테리오 클로로필 광민감제 | |
| KR101428153B1 (ko) | 점막에 적용하는 작용제 및 그것의 제조 방법 | |
| JP5889273B2 (ja) | 染色組成物 | |
| JP5889976B2 (ja) | 関節疾患に対する持続的治療効果を有する薬剤 | |
| LU85582A1 (fr) | Fractions d'acide hyaluronique ayant une activite pharmaceutique,procedes pour leur preparation et compositions pharmaceutiques les contenant | |
| JPH09169667A (ja) | 新規医薬組成物 | |
| Ghezzi et al. | Cyclosporine-loaded micelles for ocular delivery: Investigating the penetration mechanisms | |
| JP5167499B2 (ja) | 光角膜切除における角膜組織の保護のためのピレノキシンの使用 | |
| US10688196B2 (en) | Cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia | |
| JPH08503928A (ja) | 安定な高濃度のフルオレセイン製剤 | |
| CN110314252A (zh) | 胶原蛋白植入物在制备青光眼手术辅助复原物中的用途 | |
| RU2310440C1 (ru) | Раствор для защиты роговицы от повреждений | |
| Signorini et al. | A sterilizable platform based on crosslinked xanthan gum for controlled-release of polymeric micelles: Ocular application for the delivery of neuroprotective compounds to the posterior eye segment | |
| US20230201031A1 (en) | Dissolvable medical device for promoting healing of wounds | |
| EP0621779B1 (fr) | Lysinate d'indomethacine pour l'utilisation therapeutique en ophtalmologie | |
| RU2151580C1 (ru) | Способ активации пролиферации эндотелия роговицы с помощью раствора "глекомен" | |
| CZ204799A3 (cs) | Použití zelených porfyrinů pro výrobu léčiva k ošetřování sekundárního šedého zákalu | |
| RU2238738C2 (ru) | Протектор роговицы | |
| Signorinia et al. | Controlling the release of polymeric micelles with a sterilizable xanthan gum—based platform for drug delivery to the posterior eye segment | |
| MXPA99005399A (en) | Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts |